JW Marriott Indianapolis White River Ballroom A-D. 10 S West St Indianapolis, IN 46204 +1 317-860-5800
Registration is closed for this activity. paraganglioma pheochromocytoma
Intended Audience: Community medical oncologists and hematologists/oncologists and their clinical teams (NPs, PAs, nurses, and pharmacists)
JW Marriott Indianapolis - CLICK HERE for Venue Information
Advances in oncology are transforming the therapeutic landscape at a rapid pace, generating urgent needs to update clinical protocols and workflows based on emerging clinical data. On April 20th, join leading experts live in-person in Indianapolis or via livestream for this half-day event exploring application of the latest evidence in non-small cell lung cancer, melanoma, bladder cancer, and follicular lymphoma to real-world patient care. Be the first to hear key findings and real-world practice changes implemented through these 4 quality improvement initiatives conducted in the American Oncology Network. Attendees will earn continuing medical education credits and have access to the evidence-based slides from each session.
Session 1: Advancing Biomarker Testing to Inform Treatment Selection in Early-Stage NSCLC
Biomarker-directed therapies are improving outcomes for patients with early-stage non-small cell lung cancer (NSCLC) with driver mutations. Experts will engage in a comprehensive discussion on the latest advances and provide essential insights that can inform individualized treatment for patients with early-stage NSCLC with driver mutations.
Session 2: Incorporating Immunotherapy Into Practice for Early-Stage Melanoma
Recent advances in adjuvant immunotherapy are reshaping treatment prospects for patients with early-stage melanoma. Join us to discuss the latest clinical evidence, assess current barriers, and develop actionable plans for effective translation of adjuvant immunotherapy into clinical practice for early-stage melanoma.
Session 3: The Latest Evidence in Immunotherapy for Metastatic Bladder Cancer
New and emerging immunotherapies and combination approaches are revolutionizing treatment for metastatic urothelial carcinoma (mUC) patients. Join us to discuss key challenges in mUC care and actionable steps to improve patient-centered care for patients with mUC.
Session 4: Integrating Novel Bispecific Antibody Therapies Into Treatment Paradigms in Relapsed/Refractory Follicular Lymphoma
The evolving therapeutic landscape in follicular lymphoma (FL) can generate challenges in keeping clinical protocols up to date with the latest evidence, including emerging data related to novel bispecific antibody therapies. Join this expert-led interactive session to review real-world FL patient and clinical team survey data and design action plans aimed at closing identified gaps in evidence-based treatment of patients with FL.
Assistant Clinical Professor, Marian University College of Osteopathic Medicine Hematologist and Medical Oncologist Hematology Oncology of Indiana
Medical Director The Center for Cancer and Blood Disorders
Hematology Oncology of Indiana A Division of American Oncology Partners (AON)
Hematologist/Oncologist American Oncology Network Zangmeister Cancer Center Columbus, OH
Co-Director, Lung Cancer Precision Medicine Center of Excellence Assistant Professor of Oncology Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Assistant Professor and Consultant Divisions of Anatomic Pathology and Laboratory Genetics and Genomics Department of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN
Director, Cancer Immunotherapeutics Center UPMC Hillman Cancer Center Associate Professor of Medicine Division of Hematology/Oncology University of Pittsburgh School of Medicine Pittsburgh, PA
Assistant Professor of Medicine Harvard Medical School Director of Clinical Research Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute Boston, MA
Sameh Gaballa, M.D. Associate Member Department of Malignant Hematology H. Lee Moffitt Cancer Center Assistant Professor of Oncologic Sciences University of South Florida
Director of Cutaneous Oncology, GW Cancer Center Director of Dermatologic Surgery, GW Department of Dermatology Associate Professor of Dermatology & of Medicine/Oncology George Washington University School of Medicine & Health Sciences
Medical Oncology &Hematology Managing Partner, The Mark H. Zangmeister Cancer Center
Senior Director, Payer Relations PANTHERx Rare Pharmacy Indianapolis, IN
PRIME® designates this Live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 4.0 contact hours (which includes 1.75 hours of pharmacology).
This Application-based activity has been approved for 4.0 contact hours (0.4 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-24-044-L01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service (help@nabp.pharmacy).
PRIME® designates this activity for 4.0 contact hours.
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
The following individuals have no relevant financial relationships with ineligible companies to disclose:
All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.
At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.
PRIME Education, LLC (PRIME®) endorses the standards of the ACCME, AANP, ANCC, and ACPE, which require everyone in a position of controlling the content of a CME/CE activity to disclose all financial relationships with ineligible companies related to the activity content. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
▾ Show full disclosure policy
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with an ineligible company which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® will identify, review, and resolve all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
Presentations that provide information in whole or in part related to non-FDA-approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, ACCME, AANP, ACPE, ANCC, or other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME® is committed to providing access to our live CME programs for individuals with disabilities as identified in Title III of the American with Disabilities Act (ADA) for live programs. If you require assistance, call 954-718-6055 prior to attending. PRIME® is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. If you use assistive technology (ie, Braille reader, screen reader, TTY) and the format of any material on the PRIME® website's program registration pages, CME test/evaluation pages, or other areas interfere with your ability to access the information, please contact support@primeinc.org or 954-718-6055 for assistance.
To confirm your registration, please complete this short survey.
Approximately how many patients do you treat or manage monthly with the following diagnoses?
In your opinion, how important is it to assess biomarker status in patients with early-stage non-small cell lung cancer (NSCLC)?
In your practice, what factors do you consider the most important in your decision to treat early-stage melanoma with adjuvant immunotherapy? (Select your top 2)
Family/personal history of autoimmune disease
Tolerance for risk of immunotoxicities
What is the MOST challenging issue you encounter in selecting therapies for your patients with bladder cancer? (Select 1)
Tailoring FDA-approved treatment regimens to individual patients
Keeping up with clinical evidence for new and emerging therapies
Knowing when to switch therapies
Knowing how to optimally sequence therapies
Incorporating molecular testing into treatment decision-making
Delayed, pending, and/or unavailable biomarkers at the time of treatment selection
Other than cost, what are the biggest barriers you and your team encounter or expect to encounter in adopting bispecific antibody (bsAb) therapies into evidence-based, guideline-recommended relapsed/refractory follicular lymphoma (R/R FL) treatment at your clinic? (Select your top 2)
Staying up to date with the latest guidelines and clinical evidence for new and emerging bsAb therapies for FL
Identifying patients with R/R FL who would benefit from bsAb therapies
Timely recognition of FL disease progression to inform patient eligibility for bsAb therapies
Monitoring and managing adverse events associated with bsAb therapies
Patient-specific barriers (eg, patient resistance to bsAB therapies, inability to travel for inpatient administration for initial doses)
Clinic-specific barriers (eg, clinic does not have the staff or training to administer bsAb therapies in the outpatient setting; staff is unprepared to educate patients on bsAb therapies)
What question(s) do you have about the treatment and management of patients with non-small cell lung cancer, melanoma, bladder cancer, and/or follicular lymphoma? Your questions will help us tailor the content to best fit the needs of the audience. These can include general, tumor-specific, or case-related questions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© 1997–2024 PRIME Education, LLC
114 5th Ave, 15th Floor, New York, NY 10011
Advancing the science of learning and behavior change in health care
Advancing the science of learning and behavior change in health care
Advancing the science of learning and behavior change in health care
Advancing the science of learning and behavior change in health care
We need this information to award CME credit for this and future activities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Advancing the science of learning and behavior change in health care
Advancing the science of learning and behavior change in health care
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
thoracic compression fracture symptoms This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.